Press releases
September 14, 2021
BMG Pharma and HTL sign a development agreement
The agreement between BMG Pharma and HTL will allow BMG Pharma to develop and commercialize injectable products with Sodium Hyaluronate Lipoate Formate (SHLF). BMG Pharma through its patented Hyaluromimethic® Technology works on SHLF to develop solutions in aesthetic dermatology, ophthalmology, and arthrosis.
– Thanks to this agreement, BMG Pharma will globally develop new formulations of its injectable products, always with high levels of quality, stability, and safety standards.
Read more below
To see our most recent news,
Read more
news from us
-
Articles October 3, 2024HTL Biotechnology will launch its White Paper at CPHI Milan!
We are excited to announce that the HTL Biotechnology team will be attending CPHI Milan and on this occasion, we will be launching our White Paper to celebrate 90 years of discovery of Hyaluronic Acid!
-
Articles October 1, 2024New Certification for HTL Biotechnology
We are proud to announce that HTL Biotechnology has recently received Halal certification for two of our key products: DNA and HANa.
-
Articles July 5, 2024HTL Biotechnology Secures Medical Device Registration in China
Sodium DNA Raw Material Main Document (Polynucleotides) registered as a medical device (number M2024199-000) in China.